加载中
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
常规交易时段
US$7.035
−US$0.915 · -11.51%
盘中时间采用ET。市场数据可能有所延迟。
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
日内区间
当前US$7.035
52周区间
当前US$7.035
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
33
偏贵
情绪
50
多空交织
风险
50
风险偏高
动量
61
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
日内区间
当前US$7.035
52周区间
当前US$7.035
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 8198.3万 USD | 8004.6万 USD | 8321.5万 USD | 7125.5万 USD | 6111.5万 USD |
| 销售、一般及管理费用 | 2124.5万 USD | 1800.6万 USD | 1600.8万 USD | 1526.3万 USD | 1330万 USD |
| 营业费用 | 1.03亿 USD | 9805.2万 USD | 9922.3万 USD | 1.19亿 USD | 9166.5万 USD |
| 利息收入 | 104万 USD | 339万 USD | 307.5万 USD | 104.1万 USD | 6.6万 USD |
| 利息支出 | — | — | — | 104.1万 USD | — |
| 折旧和摊销 | 16.8万 USD | 13.4万 USD | 11.1万 USD | 7.7万 USD | 8.5万 USD |
| 营业利润 | −1.03亿 USD | −9805.2万 USD | −9922.3万 USD | −1.19亿 USD | −9166.5万 USD |
| 净利润 | −9717.2万 USD | −1.01亿 USD | −9361.2万 USD | −1.2亿 USD | −9294.5万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$22.13
上涨空间 214.57%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI630.56万0.00%2.3万亿 USD0.03%US$380.86-0.19%
Vanguard Extended Market ETFVXF251.61万0.00%954亿 USD0.05%US$231.92-0.69%
iShares Micro-Cap ETFIWC34.32万0.03%13.17亿 USD0.60%US$179.73-1.06%
Simplify Propel Opportunities ETFSURI24.43万0.32%7606.44万 USD2.82%US$17.25650.00%
Avantis U.S. Small Cap Equity ETFAVSC13.93万—30.79亿 USD0.25%US$69.905-0.09%
ALPS Medical Breakthroughs ETFSBIO13.47万0.07%1.87亿 USD0.50%US$51.825-3.76%
Invesco NASDAQ Future Gen 200 ETFQQQS6.18万0.27%2275.83万 USD0.20%US$40.645-1.86%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCSimplify Propel Opportunities ETFSURIAvantis U.S. Small Cap Equity ETFAVSCALPS Medical Breakthroughs ETFSBIOInvesco NASDAQ Future Gen 200 ETFQQQSAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
